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Abstract
Background: Inflammation is central to the pathogenesis of many diseases. Supplementation with selenium and
coenzyme Q10 has been shown to reduce cardiovascular mortality, and increase cardiac function in elderly persons
with a low intake of selenium. There are indications that one of the mechanisms of this positive effect is a decrease
in inflammation.
Methods: Osteopontin, osteoprotegerin, sTNF receptor 1, sTNF receptor 2 and the tumor necrosis factor-like weak
inducer of apoptosis called TWEAK, were determined in plasma after 6 months and 42months in 219 community-
living elderly persons, of whom 119 received supplements of selenium (200 μg/day) and coenzyme Q10 (200mg/day),
and 101 received a placebo. Repeated measures of variance were used to evaluate the levels, and the results were
validated through ANCOVA analyses with adjustments for important covariates.
Results: Significantly lower concentrations of four of the five biomarkers for inflammation were observed as a result of
the intervention with the supplements. Only TWEAK did not show significant differences.
Conclusion: In this sub-analysis of the intervention with selenium and coenzyme Q10 or placebo in an elderly
community-living population, biomarkers for inflammation were evaluated. A significantly lower concentration in four
of the five biomarkers tested could be demonstrated as a result of the supplementation, indicating a robust effect on
the inflammatory system. The decrease in inflammation could be one of the mechanisms behind the positive clinical
results on reduced cardiovascular morbidity and mortality reported earlier as a result of the intervention. The study is
small and should be regarded as hypothesis-generating, but nonetheless adds important data about mechanisms
presently known to increase the risk of clinical effects such as reduced cardiovascular mortality, increased cardiac
function and better health-related quality of life scoring, as previously demonstrated in the active treatment group .
Trial registration: The intervention study was registered at Clinicaltrials.gov, and has the identifier NCT01443780 and
registered on 09/30/2011.
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Introduction
Inflammation is a central process in the development
and progress of both chronic and acute diseases. In the
spectrum of cardiology, inflammation is one of the
major forces in atherosclerosis [1], in acute coronary
syndromes [2, 3], and heart failure [4–7]. In the aging
process, signs of both increasing inflammatory activity
[8], and oxidative stress are commonly observed [9].
The intake of selenium is low in Europe, and has been
estimated to be around 40 μg/day [10]. The required in-
take of selenium in order to obtain optimal function of
the intracellular enzyme glutathione peroxidase, and the
extracellular protector selenoprotein P has been dis-
cussed, and Xia et al. reported a needed intake of 75 μg/
day of selenium for adult Caucasians [11]. Moreover,
there is a need for increased intake of selenium during
conditions of increased oxidative stress and inflamma-
tion [12]. This is also applicable to persons living in re-
gions with otherwise optimal selenium content of the
soil, as in the US. There are reports indicating increased
cardiovascular disease and mortality due to a low intake
of selenium. Salonen et al. reported a 2.9 fold increase in
cardiovascular mortality in those with a low selenium in-
take [13]. Our group have also reported increased cardio-
vascular mortality associated with low intake of selenium
in healthy, elderly community-living persons [14].
Coenzyme Q10 (ubiquinone) is present in all living
cells in the body, where it acts as an important antioxi-
dant, but it is also active in the mitochondrial respiratory
chain. The endogenous production of coenzyme Q10 de-
clines after the age of 20, and in the myocardial cells it is
reduced to about half at the age of 80 years [15]. There
is an important interrelationship between selenium and
coenzyme Q10, as the cytosolic selenoenzyme thioreduc-
tase is needed for the reduction of ubiquinone to ubiqui-
nol, which is the active antioxidant form of coenzyme
Q10 [16, 17].
Our group have previously reported effects by interven-
tion with selenium and coenzyme Q10 on two biomarkers
for inflammation; sP-selectin and C-reactive protein, with
significantly fewer signs of inflammation in those receiving
active treatment, as compared with those in the placebo
group [18]. As an inhibitory effect on the inflammatory
activity caused by supplementation with selenium and co-
enzyme Q10 would be important, we wanted to validate
the effects reported earlier on sP-selectin and a high sensi-
tivity assay of CRP (hsCRP). We evaluated the impact on
five other biomarkers for inflammation; osteopontin, oste-
oprotegerin, soluble tumor necrosis factor receptor 1
(TNFr1), soluble tumor necrosis factor receptor 2
(TNFr2), and the tumor necrosis factor-like weak inducer
of apoptosis, called TWEAK.
The aim of this sub-study was to investigate a possible in-
fluence of supplementation with selenium and coenzyme
Q10 for 3.5 years on the inflammatory process, with em-
phasis on cardiovascular aspects, in an elderly Swedish
population, using five different biomarkers of inflammation
as indicators of the inflammatory activity.
Methods
Subjects
This is a secondary analysis of a subgroup of 219 indi-
viduals from a prospective randomized double-blind
placebo-controlled trial in an elderly community popula-
tion of 443 individuals with an age range of 70–88 years.
We were able to report significantly reduced cardiovas-
cular mortality, increased cardiovascular function, and
less concentration of the cardiac peptide NT-proBNP as
a response to less myocardial wall tension as a result of
the intervention. The trial has been previously reported
[19, 20]. The participants in the main study received the
intervention for 48 months, and were re-examined every
6 months. At inclusion, new patient records were ob-
tained, all participants went through a clinical examin-
ation, the New York Heart Association functional class
(NYHA class) was assessed, and an ECG and Doppler
echocardiographical examinations were performed with
the participant in the left lateral position. The ejection
fraction (EF) readings were categorized into four classes,
with interclass limits placed at 30, 40 and 50% [21, 22].
Normal systolic function was defined as EF ≥ 50%, while se-
verely impaired systolic function was defined as EF < 30%.
Informed consent was obtained from each patient. In
the main study, 221 individuals received active supple-
mentation of 200 μg/day organic selenium (SelenoPre-
cise®, Pharma Nord, Denmark), plus 200 mg/day of
coenzyme Q10 (Bio-Quinon®, Pharma Nord, Denmark),
and 222 individuals received a placebo.
The present subgroup comprised 219 participants (118
individuals on active treatment and 101 on placebo), and
the figures were based on the number of participants
still living and within the study having delivered blood
samples both after six and after 42 months.
Ethical approval and consent to participate
The study was approved by the Regional Ethical Com-
mittee and conforms to the ethical guidelines of the
1975 Declaration of Helsinki. (The Medical Product
Agency declined to review the study protocol since the
study was not considered a trial of a medication for a
certain disease but rather one of food supplement com-
modities that are commercially available). This study
was registered at Clinicaltrials.gov, and has the identifier
NCT01443780. Since it was not mandatory to register at
the time of the study start, the study has been registered
retrospectively.
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Biochemical analyses
Blood samples were collected after six and 42months
while the participants were resting in a supine position.
Pre-chilled, EDTA vials containing plasma were used. The
vials were centrifuged at 3000 g, + 4 °C, and were then fro-
zen at − 70 °C. No sample was thawed more than once.
Determination of the inflammatory biomarkers
Plasma Osteopontin, Osteoprotegerin, TNFr1, TNFr2
and TWEAK/ TNFSF12 were analyzed using commer-
cial ELISA kits (DY1433, DY805, DY321B, DY726 and
DY1090, R&D Systems, Minneapolis, MN, USA). The
assays had a total coefficient of variation of approxi-
mately 6%. Those performing the measurements were
blinded as to the purpose of the study and without
knowledge of the clinical data.
Statistical methods
Descriptive data are presented as percentages or mean ±
SD. A Student’s unpaired two-sided T-test was used for
continuous variables and the chi-square test was used
for analysis of one discrete variable. Repeated measures of
variance were used in order to obtain better information
on the individual changes in the concentration of the bio-
marker analyzed, compared to group mean values.
As the analysis of variance (ANOVA) algorithm can han-
dle a slight non-Gaussian distribution, non-transformed
data were applied in the repeated measures of variance
evaluation. In the analysis of covariance (ANCOVA) evalu-
ation, both transformed and non-transformed data were
applied, with no significant difference in the results.
In the ANCOVA evaluation, the biomarker concentra-
tion after 42 months was used as an independent vari-
able. In the model, adjustments were made for age,
smoking, hypertension, ischemic heart disease (IHD),
biomarker concentration after 6 months, hs-CRP, and
supplementation with selenium and coenzyme Q10.
P-values < 0.05 were considered significant, based on a
two-sided evaluation. All data were analyzed using standard
software (Statistica v. 13.2, Dell Inc., Tulsa, OK).
Results
The study population in this sub-study consisted of 219
participants, of which 118 received active treatment, and
101 received placebo. In the population, 17% had dia-
betes, 70% had hypertension and 17% had IHD (Table 1;
submitted as separate file due to table size). It could also
be seen that 13% had treatment with ACE inhibitors,
and 77% had treatment with beta-blockers.
From the evaluations at inclusion, no difference could
be seen between the two groups as based on the group
mean evaluation and thus the two populations were con-
sidered balanced (Table 1).
Osteopontin and intervention with selenium and
coenzyme Q10
At the start of the sub-study, that is after 6 months, there
was no significant difference in osteopontin concentration
between the active treatment group, and the placebo group
(65,913mmol/L vs. 65,395mmol/L; T = 0.1; P = 0.92).
However, after 42months a highly significant difference be-
tween the two groups could be found (60,067mmol/L vs.
71,632mmol/L; T = 3.72; P = 0.0003) with a lower concen-
tration in the active treatment group.
Analyzing the placebo group, a borderline significant
increase in the concentration of osteopontin could be
seen between six months and 42months (65,395mmol/L
vs. 71,633mmol/L; T = 1.90; P = 0.059); however, in the
active group no significant change in concentration could
be found (65,913mmol/L vs. 60,067mmol/L; T = 1.17;
P = 0.24).
Table 1 Baseline characteristics of the study population
receiving intervention of a dietary supplementation of selenium
and coenzyme Q10 combined during 4 years
Active Placebo p-value
N 118 101
Age years mean (SD) 76.2 (3.1) 76.3 (3.1) 0.74
Males/Females n 58/60 43/58
History
Diabetes n (%) 20 (16.9) 18 (17.8) 0.87
Hypertension n (%) 81 (68.5) 72 (71.3) 0.67
IHD n (%) 22 (18.6) 16 (15.8) 0.59
NYHA class I n (%) 71 (60.2) 58 (57.4) 0.68
NYHA class II n (%) 29 (24.6) 30 (29.7) 0.39
NYHA class III n (%) 18 (15.3) 12 (11.9) 0.47
NYHA class IV n (%) 0 0
Medications
Anticoagulants n (%) 9 (7.6) 9 (8.9) 0.73
ACEI n (%) 15 (12.7) 14 (13.9) 0.80
ARB n (%) 4 (3.4) 7 (6.9) 0.23
Beta blockers n (%) 44 (37.3) 33 (32.7) 0.48
Digitalis n (%) 5 (4.2) 1 (0.9) 0.14
Diuretics n (%) 39 (33.1) 33 (32.7) 0.95
Statins n (%) 27 (22.9) 17 (16.8) 0.27
Examinations
EF < 40% n (%) 7 (5.9) 4 (4.0) 0.51
Atrial fibrillation n (%) 6 (5.1) 7 (6.9) 0.56
Lab
Hb < 120 g/L (%) 11 (9.3) 9 (8.9) 0.92
hsCRP g/L (SD) 2.60 (2.60) 5.60 (22.15) 0.34
Note: ACEI ACE- inhibitors, ARB Angiotension receptor blockers, EF Ejection
fraction, hsCRP C-reactive protein analysed with high sensitivity assay, IHD
Ischemic heart disease, IQR Inter quartile range, NYHA New York Heart
Association functional class, SD Standard Deviation
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Applying repeated measures of variance, a highly sig-
nificant difference in concentration of osteopontin be-
tween the placebo group and the active group could be
seen (F = 4.59; P = 0.03) with a lower concentration in
the active treatment group (Fig. 1).
Validating the results through an ANCOVA evalu-
ation, a significant difference in osteopontin concentra-
tion could be seen between those receiving active
treatment and those receiving placebo, with a lower con-
centration in the active treatment group (P = 0.004).
Osteoprotegerin and intervention with selenium and
coenzyme Q10
After 6 months, there was no significant difference in
osteoprotegerin concentration between the active treat-
ment group, and the placebo group (5931 mmol/L vs.
5725 mmol/L; T = 0.5; P = 0.61). However, after 42
months a highly significant difference between the two
groups could be found (5877 mmol/L vs. 6552 mmol/L;
T = 2.73; P = 0.007) with a lower concentration in the ac-
tive treatment group.
Validating the above results of osteoprotegerin con-
centration difference, an ANCOVA evaluation was per-
formed, where the biomarker displayed a significantly
lower concentration in the active treatment group com-
pared to the placebo group, and this was also found after
adjustments of important covariables (P = 0.04).
Repeated measures of variance evaluation also demon-
strated a significant difference in osteoprotegerin with a
lower concentration in the active treatment group (F = 4.61;
P = 0.03) (Fig. 2).
TNFr1 and intervention with selenium and coenzyme Q10
No significant difference in TNFr1 concentration could
be seen between the active treatment group, and the pla-
cebo group after 6 months of intervention (2873 mmol/
L vs. 2903mmol/L; T = 0.2; P = 0.81). After 42 months, a
highly significant difference between the two groups was
found with a higher concentration in the placebo group
(3012 mmol/L vs. 2656 mmol/L; T = 2.83; P = 0.005).
In the placebo group we found no significant change in
the concentration at 6 months in comparison with that at
42months (2902mmol/L vs. 3012mmol/L; T = 0.78; P =
0.44). However, in the active treatment group, a significant
reduction of concentration could be found during the same
period (2873mmol/L vs. 2656mmol/L; T = 1.98; P = 0.049).
By applying repeated measures of variance, a signifi-
cant difference in concentrations could be demonstrated
(F = 4.81; P = 0.03) with a lower concentration in the ac-
tive treatment group (Fig. 3).
TNFr2 and intervention with selenium and coenzyme Q10
No significant difference in concentrations of TNFr2
could be seen between the active treatment and the pla-
cebo groups after 6 months of intervention (5621mmol/L
vs. 5569mmol/L; T = 0.21; P = 0.84). However, after 42
months of intervention a slightly lowered level of concen-
tration of TNFr2 could be seen in the active treatment
group as compared to the placebo group (5398mmol/L
vs. 5984mmol/L; T = 1.95; P = 0.05).
Validating the result by applying the ANCOVA model,
the significant effect of intervention with selenium and
coenzyme Q10 on TNFr2 after 42 months remained
Fig. 1 Concentration of Osteopontin after 6 and 42 months in the placebo and selenium and coenzyme Q10 treatment groups in the total study
population. Note: Current effect: F(1, 216) = 4.5913, p = .03325. Note: Evaluation performed by use of repeated measures of variance methodology.
Note: Blue curve: Placebo; Red curve: Active treatment group. Values ±95% C, Vertical bars denote 0.95 confidence intervals
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even after adjustments with several important covariates
(F = 4.49; P = 0.04), that is, there was a lower concentra-
tion of the biomarker in the active treatment group.
Applying repeated measures of variance methodology,
a highly significant difference in concentration of TNFr2
between the active treatment group and the placebo
group could be found (F = 5.63; P = 0.02) with a lower
concentration in the active treatment group (Fig. 4).
TWEAK and intervention with selenium and coenzyme
Q10
After 6 months, no difference in concentration of TWEAK
could be found between the active treatment group and the
placebo group (3820mmol/L vs. 4250mmol/L; T = 0.25;
P = 0.80). After 42months of intervention, still no difference
between the two groups could be seen (4014mmol/L vs.
4959mmol/L; T = 0.53; P = 0.60). Moreover, no difference
Fig. 2 Concentration of Osteoprotegerin after 6 and 42 months in the placebo and selenium and coenzyme Q10 treatment groups in the total
study population. Note: Current effect: F(1, 214) = 4.6059, p = .03299. Note: Evaluation performed by use of repeated measures of variance
methodology. Note: Blue curve: Placebo; Red curve: Active treatment group. Values ±95% CI. Vertical bars denote 0.95 confidence intervals
Fig. 3 Concentration of TNFr1 after 6 and 42months in the placebo and selenium and coenzyme Q10 treatment groups in the total study
population. Note: Evaluation performed by use of repeated measures of variance methodology. Note: Current effect: F(1, 215) = 4.8064, p = .02943.
Note: Blue curve: Placebo; Red curve: Active treatment group. Values ±95% CI. Vertical bars denote 0.95 confidence intervals
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be demonstrated by applying repeated measures of variance
(F = 0.14; P = 0.71).
Discussion
In this study, we conducted further examination of the
impact of supplementation with selenium and coenzyme
Q10 on inflammation using five different biomarkers. In
many cardiovascular diseases, inflammation is one of the
most important components of the disease; thus, a pos-
sible positive influence of the disease through reduced
inflammation would also have an impact on the need for
health resources of society.
The two bone biomarkers osteopontin and osteopro-
tegerin are of special interest as they are also associated
with inflammation.
Osteopontin levels are significantly associated with the
presence and the extent of cardiovascular disease inde-
pendently of traditional risk factors [23]. Also, osteopon-
tin levels are higher in patients presenting signs of
vascular calcification than those without and correlate
with the number of segments affected. An increased
concentration of osteoprotegerin has been consistently
associated with the incidence and prevalence of coronary
artery disease [24].
We have previously reported positive effects on two bio-
markers of inflammation; sP-selectin, and hsCRP [18].
However, as both biomarkers may also reflect processes
other than inflammation, we wanted to validate the result
by applying five other biomarkers of inflammation.
Although the two related biomarkers, osteopontin and
osteoprotegerin, are involved in the bone metabolism, it
is well known that they also reflect inflammation, and
they can therefore be used as biomarkers for inflamma-
tory activity.
Kim et al. demonstrated increased apoptosis of endo-
thelial progenitor cells as a result of an increased level of
osteoprotegerin, and they used free radical scavengers to
negate the effect [25]. The present results show that
intervention with selenium and coenzyme Q10 reduced
levels of osteoprotegerin in line with the reduced cardio-
vascular mortality. A previously reported association be-
tween the level of osteopontin and cardiovascular events
for those with carotid artery stenosis further strengthens
our reasoning [26].
sTNFr1 and r2 are both reported to play an active part
in inflammation [27, 28]. There is also an association be-
tween the concentration of both receptors, and frailty in
elderly persons. This association with frailty is stronger
than that with age, which could be interpreted to mean
that for the individual, the inflammatory activity is im-
portant as regards overall health [29]. This concurs with
the results from our study, where intervention with sel-
enium and coenzyme Q10 showed effects both on clin-
ical endpoints and on biomarkers for oxidative stress
[20], inflammation [18] and microRNA [30].
Regarding the biomarker TWEAK, the literature re-
ports not only associations between the concentration of
the biomarker and inflammation of the skin [31], but
also an inflammatory-related up-regulation of endothe-
lial cells accompanying increased levels of TWEAK [32].
Therefore, we expected that the intervention with selen-
ium and coenzyme Q10 would reduce the concentration
Fig. 4 Concentration of TNFr2 after 6 and 42months in the placebo and selenium and coenzyme Q10 treatment groups in the total study
population. Note: Evaluation performed by use of repeated measures of variance methodology. Note: Current effect: F(1, 215) = 5.6269, p = .01857.
Note: Blue curve: Placebo; Red curve: Active treatment group. Values ±95% CI. Vertical bars denote 0.95 confidence intervals
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of TWEAK; however, no significant change occurred.
The reason for this is presently unclear. It has been re-
ported, however, that using a plasma concentration of
TWEAK, as we have done, gives a significantly lower
concentration of TWEAK, as compared to a serum con-
centration of TWEAK [33]. However, this insufficient re-
liability should affect both treatment groups.
When interpreting the signs of decreased inflammation
as a result of the intervention, an attractive explanation is
the fact that the present ageing population has a subopti-
mal intake of selenium, and a suboptimal endogenous
production of active coenzyme Q10 (ubiquinol). As three
of the most important selenoenzymes (glutathione perox-
idase, thioredoxin reductase, and selenoprotein P) are im-
portant in the anti-oxidative defense, it is reasonable that
a normalization of the deficiencies of the two essential
substances would lead to improved global health and re-
duced inflammatory activity.
Our group has previously reported signs of reduced
oxidative stress supporting the mechanisms discussed
above [20] . Our previous observations of changed ex-
pression of microRNA as a result of the intervention
[30] are also compatible with the hypothesis that
normalization of the ubiquinol and selenium status in
the studied group has a protective potential as regards
inflammation and cardiovascular health. From the pa-
tient perspective, we have also reported improved
health-related quality of life, and more days outside hos-
pital, as a result of the intervention [34]. Also, a reduced
cardiovascular mortality after 10 and after 12 years as a
result of four years of intervention of selenium and co-
enzyme Q10 has also been presented [35, 36]. In order
to evaluate a possible association between the level of in-
flammation biomarker and mortality, the cardiovascular
mortality after 12 years have been evaluated in the 1st
versus the 4th quartiles of concentration of each bio-
marker (Table 2).
From the obtained results in the present sub-study,
it is clear that intervention with selenium and coen-
zyme Q10 gives significantly decreased inflammation
in four out of five biomarkers of inflammation evalu-
ated, when compared with placebo. This could be one
of the mechanisms explaining the apparent protection
against cardiovascular events reported previously as a
result of the intervention [19].
Limitations
The studied population was of limited size, 219 individ-
uals; therefore, the reported results should be interpreted
with caution. However, as the differences between the ac-
tive treatment and placebo groups were highly significant,
it is probable that the results reflect real changes. The re-
port should be regarded as hypothesis-generating, and as
such it has interesting information that should be sub-
jected to further research.
The study population was not sampled primarily, but
chosen because they lived in the same rural community
and were in the same age stratum. The results could
therefore be subject to bias because of a lower threshold
to participate among those with known or unknown dis-
ease, but with symptoms, hoping for a diagnosis or treat-
ment adjustment, leading to a greater preponderance of
those individuals. This situation could theoretically re-
sult in an even higher level of inflammation compared
to other healthy populations of corresponding age. How-
ever, as the main study population was randomized into
two groups, it could be expected that those given active
treatment would have a similar health situation as those
on placebo, as was also seen from the balanced covari-
ates in the baseline characteristics.
Furthermore, the study population represented a spe-
cific age stratum. It is therefore difficult to extrapolate
the obtained information into other age groups.
Finally, the study population was an ethnically
homogenous Caucasian population; thus, we do not
know if the information could be applied to other
populations.
Conclusion
Here we report on the impact following intervention
with selenium and coenzyme Q10 on inflammation as
measured by the concentrations of the five biomarkers:
osteopontin, osteoprotegerin, sTNFr1, sTNFr2 and
TWEAK. In all, except for TWEAK, the intervention
caused a significant reduction in the biomarker concen-
trations. These results strengthen the previous results
Table 2 Relation between cardiovascular mortality after 12 years of follow-up, and the 1st and 4th quartiles of concentration of the
five biomarkers for inflammation evaluated
Variable CV mortality Q1 CV mortality Q4 Χ2-value p-value
Osteopontin, n (%) 19 (17.4) 36 (33.0) 7.03 0.008
Osteoprotegerin, n (%) 20 (18.5) 35 (33.0) 5.89 0.015
sTNFr1, n (%) 17 (15.7) 37 (34.6) 10.14 0.002
sTNFr2, n (%) 23 (21.3) 32 (29.6) 1.98 0.16
TWEAK, n (%) 30 (27.8) 35 (32.4) 0.55 0.46
Note: Q1: 1st quartile; Q4: 4th quartile
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reported for sP-selectin and C-reactive protein, which also
showed the same signs of reduced inflammatory activity.
The positive impact on inflammation could be part of
the mechanism explaining the positive clinical results re-
ported earlier. However, as the sample size was limited,
the results should be interpreted with caution.
Abbreviations
ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; EF: Ejection
fraction; hsCRP: high sensitivity assay of CRP; IHD: Ischemic heart disease;
NYHA class: New York Heart Association functional class; TNFr1: soluble
tumor necrosis factor receptor 1; TNFr2: soluble tumor necrosis factor
receptor 2; TNF-α: Tumor necrosis factor-α; TWEAK: the tumor necrosis factor
like weak inducer of apoptosis, called TWEAK
Acknowledgements
We would like to thank study nurse Anette Gylling for all valuable help in
the preparation of all blood samples.
Funding
Part of the analysis costs was supported by grants from Pharma Nord Aps,
Denmark, the County Council of Östergötland, Linköping University.
The funding organizations had no role in the design, management, analysis,
or interpretation of the data, nor in the preparation, review or approval of
the manuscript. No economic compensation was distributed.
Availability of data and materials
Under Swedish Law, the authors cannot share the data underlying this study
and cannot do any further research than what is specified in the ethical
permissions application. For inquires on the data, researchers should first
reach out to the owner of the database, the University of Linköping. Please
reach out to the corresponding author with requests and for assistance with
data requests. If the university approves the request, researchers can submit
an application to the Regional Ethical Review Board for the specific research
question that the researcher wants to examine.
Authors' contributions
Conceived and designed the experiments: Alehagen, Larsson. Conducted
research: Alehagen, Larsson. Analyzed the data: Alehagen, Aaseth, Alexander.
Contributed reagents/material/analysis tools: Alehagen, Larsson. Wrote the
manuscript: Alehagen, Aaseth, Alexander, Larsson. Had the primary
responsibility for final content: Alehagen. All authors have read and
approved the manuscript.
Ethics approval and consent to participate
The study protocol has previously been published [35]. The study was
approved by the Regional Ethical Committee in Linköping (Diary no. 03–176)
and conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
The intervention study was registered at Clinicaltrials.gov, and has the
identifier NCT01443780.
Written, informed consent was obtained from all patients.
Consent for publication
Informed consent was obtained from each patient.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Cardiovascular Medicine, Department of Medical and Health
Sciences, Linköping University, SE-581 85 Linköping, Sweden. 2Norwegian
Institute of Public Health, N-0403 Oslo, Norway. 3Research Department,
Innlandet Hospital Trust, Brumunddal, Norway. 4Inland Norway University of
Applied Sciences, N-2411 Elverum, Norway. 5Department of Medical
Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.
Received: 13 February 2019 Accepted: 12 March 2019
References
1. Rafieian-Kopaei M, et al. Atherosclerosis: process, indicators, risk factors and
new hopes. Int J Prev Med. 2014;5(8):927–46.
2. Shantsila E, Tapp LD, Lip GY. Free light chains in patients with acute
coronary syndromes: relationships to inflammation and renal function. Int J
Cardiol. 2015;185:322–7.
3. Libby P, et al. Inflammation and its resolution as determinants of acute
coronary syndromes. Circ Res. 2014;114(12):1867–79.
4. Glezeva N, et al. Exaggerated inflammation and monocytosis associate with
diastolic dysfunction in heart failure with preserved ejection fraction:
evidence of M2 macrophage activation in disease pathogenesis. J Card Fail.
2015;21(2):167–77.
5. Matsubara J, et al. Pentraxin 3 is a new inflammatory marker correlated with
left ventricular diastolic dysfunction and heart failure with normal ejection
fraction. J Am Coll Cardiol. 2011;57(7):861–9.
6. Kalogeropoulos AP, et al. High-sensitivity C-reactive protein in acute heart
failure: insights from the ASCEND-HF trial. J Card Fail. 2014;20(5):319–26.
7. Askevold ET, et al. Interleukin-6 signaling, soluble glycoprotein 130, and
inflammation in heart failure. Curr Heart Fail Rep. 2014;11(2):146–55.
8. Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects
aging, metabolic syndrome and cardiovascular disease. Interdiscip Top
Gerontol. 2015;40:99–106.
9. Abramson JL, et al. Association between novel oxidative stress markers and
C-reactive protein among adults without clinical coronary heart disease.
Atherosclerosis. 2005;178(1):115–21.
10. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256–68.
11. Xia Y, et al. Optimization of selenoprotein P and other plasma selenium
biomarkers for the assessment of the selenium nutritional requirement: a
placebo-controlled, double-blind study of selenomethionine
supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr.
2010;92(3):525–31.
12. Manzanares W, et al. Serum selenium and glutathione peroxidase-3 activity:
biomarkers of systemic inflammation in the critically ill? Intensive Care Med.
2009;35(5):882–9.
13. Salonen JT, et al. Association between cardiovascular death and myocardial
infarction and serum selenium in a matched-pair longitudinal study. Lancet.
1982;2(8291):175–9.
14. Alehagen U, et al. Relatively high mortality risk in elderly Swedish subjects
with low selenium status. Eur J Clin Nutr. 2016;70(1):91–6.
15. Sanoobar M, et al. Coenzyme Q10 supplementation ameliorates
inflammatory markers in patients with multiple sclerosis: a double blind,
placebo, controlled randomized clinical trial. Nutr Neurosci. 2014.
16. Xia L, et al. The mammalian cytosolic selenoenzyme thioredoxin reductase
reduces ubiquinone. A novel mechanism for defense against oxidative
stress. J Biol Chem. 2003;278(4):2141–6.
17. Norman JA, et al. Degradation of brain natriuretic peptide by neutral
endopeptidase: species specific sites of proteolysis determined by mass
spectrometry. Biochem Biophys Res Commun. 1991;175(1):22–30.
18. Alehagen U, et al. Levels of sP-selectin and hs-CRP decrease with dietary
intervention with selenium and coenzyme Q10 combined: a secondary
analysis of a randomized clinical trial. PLoS One. 2015;10(9):e0137680.
19. Alehagen U, et al. Cardiovascular mortality and N-terminal-proBNP reduced
after combined selenium and coenzyme Q10 supplementation: a 5-year
prospective randomized double-blind placebo-controlled trial among
elderly Swedish citizens. Int J Cardiol. 2013;167(5):1860–6.
20. Alehagen U, Aaseth J, Johansson P. Less increase of copeptin and MR-
proADM due to intervention with selenium and coenzyme Q10
combined: results from a 4-year prospective randomized double-blind
placebo-controlled trial among elderly Swedish citizens. Biofactors. 2015;
41(6):443–52.
21. Jensen-Urstad K, et al. Comparison of different echocardiographic methods
with radionuclide imaging for measuring left ventricular ejection fraction
during acute myocardial infarction treated by thrombolytic therapy. Am J
Cardiol. 1998;81(5):538–44.
22. van Royen N, et al. Comparison and reproducibility of visual
echocardiographic and quantitative radionuclide left ventricular ejection
fractions. Am J Cardiol. 1996;77(10):843–50.
Alehagen et al. Journal of Inflammation            (2019) 16:5 Page 8 of 9
23. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule
regulating chronic inflammation and vascular disease. Arterioscler Thromb
Vasc Biol. 2007;27(11):2302–9.
24. Venuraju SM, et al. Osteoprotegerin as a predictor of coronary artery disease
and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):
2049–61.
25. Kim JY, et al. Osteoprotegerin causes apoptosis of endothelial progenitor
cells by induction of oxidative stress. Arthritis Rheum. 2013;65(8):2172–82.
26. Carbone F, et al. Serum levels of osteopontin predict major adverse
cardiovascular events in patients with severe carotid artery stenosis. Int J
Cardiol. 2018;255:195–9.
27. Kneilling M, et al. Direct crosstalk between mast cell-TNF and TNFR1-
expressing endothelia mediates local tissue inflammation. Blood. 2009;
114(8):1696–706.
28. Steeland S, et al. Simultaneous inhibition of tumor necrosis factor receptor 1
and matrix metalloproteinase 8 completely protects against acute
inflammation and sepsis. Crit Care Med. 2018;46(1):e67–75.
29. Van Epps P, et al. Frailty has a stronger association with inflammation than
age in older veterans. Immun Ageing. 2016;13:27.
30. Alehagen U, et al. Significant changes in circulating microRNA by dietary
supplementation of selenium and coenzyme Q10 in healthy elderly males.
A subgroup analysis of a prospective randomized double-blind placebo-
controlled trial among elderly Swedish citizens. PLoS One. 2017;12(4):
e0174880.
31. Liu Q, Xiao S, Xia Y. TWEAK/Fn14 activation participates in skin
inflammation. Mediat Inflamm. 2017;2017:6746870.
32. Martinez-Miguel P, et al. Tweak up-regulates endothelin-1 system in mouse
and human endothelial cells. Cardiovasc Res. 2017;113(2):207–21.
33. Basso D, et al. Relevance of pre-analytical blood management on the
emerging cardiovascular protein biomarkers TWEAK and HMGB1 and on
miRNA serum and plasma profiling. Clin Biochem. 2017;50(4–5):186–93.
34. Johansson P, et al. Improved health-related quality of life, and more days
out of hospital with supplementation with selenium and coenzyme Q10
combined. Results from a double blind, placebo-controlled prospective
study. J Nutr Health Aging. 2015;19(9):870–7.
35. Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10
years after supplementation with selenium and coenzyme Q10 for four
years: follow-up results of a prospective randomized double-blind placebo-
controlled trial in elderly citizens. PLoS One. 2015;10(12):e0141641.
36. Alehagen U, et al. Still reduced cardiovascular mortality 12 years after
supplementation with selenium and coenzyme Q10 for four years: a
validation of previous 10-year follow-up results of a prospective randomized
double-blind placebo-controlled trial in elderly. PLoS One. 2018;13(4):
e0193120.
Alehagen et al. Journal of Inflammation            (2019) 16:5 Page 9 of 9
